Aranidipine: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Antihypertensive medication}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| IUPAC_name = 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, diethyl ester | |||
| image = Aranidipine.svg | |||
| width = 200 | |||
| tradename = Sapresta | |||
| legal_status = Rx-only | |||
| routes_of_administration = Oral | |||
| bioavailability = 20% | |||
| protein_bound = 95% | |||
| metabolism = Hepatic | |||
| elimination_half-life = 8 hours | |||
| excretion = Renal | |||
}} | |||
'''Aranidipine''' is a [[calcium channel blocker]] used as an [[antihypertensive]] agent. It is primarily prescribed for the management of [[hypertension]] (high blood pressure). Aranidipine belongs to the [[dihydropyridine]] class of calcium channel blockers, which are known for their ability to selectively inhibit the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, leading to vasodilation and reduced blood pressure. | |||
==Pharmacology== | ==Pharmacology== | ||
Aranidipine works by | Aranidipine works by blocking the L-type calcium channels in the smooth muscle of the vasculature. This action prevents calcium from entering the cells, which is necessary for muscle contraction. As a result, the blood vessels relax and dilate, leading to a decrease in [[systemic vascular resistance]] and a subsequent reduction in blood pressure. | ||
===Pharmacokinetics=== | |||
Aranidipine is administered orally and has a bioavailability of approximately 20%. It is highly protein-bound (95%) and undergoes extensive hepatic metabolism. The elimination half-life of aranidipine is about 8 hours, and it is primarily excreted through the renal route. | |||
==Clinical Use== | ==Clinical Use== | ||
Aranidipine is | Aranidipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents such as [[ACE inhibitors]], [[angiotensin II receptor blockers]], or [[diuretics]]. The choice of combination therapy depends on the individual patient's response and the presence of comorbid conditions. | ||
==Side Effects== | ==Side Effects== | ||
Common side effects of aranidipine include headache, dizziness, flushing, and peripheral edema. These effects are generally mild and tend to diminish with continued use. As with other calcium channel blockers, there is a potential for reflex tachycardia due to the vasodilatory effects. | |||
==Related | ==Related pages== | ||
* [[Hypertension]] | |||
* [[Calcium channel blocker]] | * [[Calcium channel blocker]] | ||
* [[ | * [[Dihydropyridine]] | ||
* [[ | * [[Antihypertensive drug]] | ||
[[ | ==Gallery== | ||
[[ | <gallery> | ||
[[ | File:Hydrochlorothiazide.png|[[Hydrochlorothiazide]] | ||
File:Captopril_skeletal.svg|[[Captopril]] | |||
File:Valsartan.svg|[[Valsartan]] | |||
File:Propranolol.svg|[[Propranolol]] | |||
</gallery> | |||
[[Category:Calcium channel blockers]] | |||
[[Category:Antihypertensive agents]] | |||
Revision as of 19:01, 11 February 2025
Antihypertensive medication
| Aranidipine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | 20% |
| Metabolism | Hepatic |
| Elimination half-life | 8 hours |
| Excretion | Renal |
| Legal status | Rx-only |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Aranidipine is a calcium channel blocker used as an antihypertensive agent. It is primarily prescribed for the management of hypertension (high blood pressure). Aranidipine belongs to the dihydropyridine class of calcium channel blockers, which are known for their ability to selectively inhibit the influx of calcium ions into vascular smooth muscle and cardiac muscle cells, leading to vasodilation and reduced blood pressure.
Pharmacology
Aranidipine works by blocking the L-type calcium channels in the smooth muscle of the vasculature. This action prevents calcium from entering the cells, which is necessary for muscle contraction. As a result, the blood vessels relax and dilate, leading to a decrease in systemic vascular resistance and a subsequent reduction in blood pressure.
Pharmacokinetics
Aranidipine is administered orally and has a bioavailability of approximately 20%. It is highly protein-bound (95%) and undergoes extensive hepatic metabolism. The elimination half-life of aranidipine is about 8 hours, and it is primarily excreted through the renal route.
Clinical Use
Aranidipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents such as ACE inhibitors, angiotensin II receptor blockers, or diuretics. The choice of combination therapy depends on the individual patient's response and the presence of comorbid conditions.
Side Effects
Common side effects of aranidipine include headache, dizziness, flushing, and peripheral edema. These effects are generally mild and tend to diminish with continued use. As with other calcium channel blockers, there is a potential for reflex tachycardia due to the vasodilatory effects.
